Senti Biosciences shares surge 19.25% premarket after reporting 50% ORR in Phase 1 trial of SENTI-202 and receiving FDA RMAT designation.

Senti Biosciences (SNTI) surged 19.25% in premarket trading following the release of promising Phase 1 clinical trial data for its lead candidate, SENTI-202, targeting relapsed/refractory AML. The trial reported a 50% overall response rate and 42% complete remission rate at the recommended Phase 2 dose, alongside FDA RMAT and Orphan Drug designations, which accelerate regulatory pathways. These developments, coupled with Leerink’s initiation of coverage with an Outperform rating and $6 price target, reinforced investor optimism. The positive pharmacodynamic data validating SENTI-202’s selective targeting of AML cells and its safety profile further underscored the therapy’s potential, driving the sharp premarket rally despite underlying financial challenges.